Table 2.
Continued
| Agent | Trial number (Trial name) | Phase | Number of patients | Arm | Year | Status |
|---|---|---|---|---|---|---|
| Datopotamab deruxtecan (Dato-Dxd) (TROP2-ADC) | NCT04484142 (TROPION-Lung05) | II | 137 | Dato-DXd | 2020 | Active, not recruiting |
| NCT04656652 (TROPION-Lung01) | III | 590 | Dato-DXd Docetaxel |
2020 | Recruiting | |
| Telisotuzumab vedotin (Teliso-V) (MET-ADC) | NCT02099058 | I | 260 | Teliso-V Teliso-V + erlotinib Teliso-V + nivolumab Teliso-V + osimertinib |
2014 | Recruiting |
| NCT04928846 | III | 698 | Teliso-V Docetaxel |
2021 | Recruiting | |
| EGFR-MET bispecific antibody | ||||||
| Amivantamab | NCT02609776 (CHRYSALIS) | I | 780 | Amivantamab + lazertinib | 2015 | Recruiting |
| NCT04077463 (CHRYSALIS-2) | I/Ib | 460 | Lazertinib Amivantamab + lazertinib Amivantamab + Lazertinib + CBDCA + PEM |
2019 | Recruiting | |
| NCT04988295 (MARIPOSA-2) | III | 600 | Amivantamab + Lazertinib + CBDCA + PEM CBDCA + PEM Amivantamab + CBDCA + PEM |
2021 | Recruiting | |
| Immune checkpoint inhibitor | ||||||
| ICI + chemotherapy | NCT02864251 (Checkmate 722) | III | 367 | Nivolumab + CDDP/CBDCA + PEM CDDP/CBDCA + PEM |
2016 | Completed |
| NCT03515837 (KEYNOTE-789) | III | 492 | Pembrolizumab + CDDP/CBDCA + PEM CDDP/CBDCA + PEM |
2018 | Active, not recruiting | |
| NCT03802240 (ORIENT-31) | III | 600 | Sintilimab + IBI305 + CDDP + PEM Sintilimab + placebo + CDDP + PEM Placebo + placebo + CDDP + PEM |
2019 | Recruiting | |
| Multiple study treatment (platform study) | ||||||
| NCT03944772 (ORCHARD) | II | 250 | Osimertinib + savolitinib Osimertinib + gefitinib Osimertinib + necitumumab CBDCA + PEM + durvalumab Osimertinib + alectinib Osimertinib + selpercatinib CDDP/CBDCA + etoposide + durvalumab Osimertinib + CDDP/CBDCA + PEM Osimertinib + selumetinib Osimertinib + Dato-Dxd |
2019 | Recruiting | |
Abbreviations: CBDCA, carboplatin; PEM, pemetrexed; CDDP, cisplatin: ADC, antibody–drug conjugate; ICI, immune checkpoint inhibitor.